Why the study?
Prior studies of CCM used a 3-lead Optimizer system; a new 2-lead system eliminating the atrial lead required testing for safety and effectiveness compared with the 3-lead system.
Does the 2-lead Optimizer system improve peak VO2 in patients with symptomatic heart failure (LVEF 25-45%) compared to a 3-lead system?
Comparison
Optimizer 2-lead system vs historical 3-lead system controls from FIX-HF-5C
Design
Single-arm trial compared with historical trial controls
Follow-up
24 weeks
Authors
Loading...
May cut lead complications and extend CCM to AF; leaves open randomized confirmation versus contemporary GDMT.
Does the 2-lead Optimizer system improve peak VO2 in patients with symptomatic heart failure (LVEF 25-45%) compared to a 3-lead system?
The 2-lead Optimizer system for cardiac contractility modulation provides comparable CCM delivery to the 3-lead system with fewer device-related adverse events and improved peak VO2.
Wiegn et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: